logo-loader
viewAqualung Therapeutics

Aqualung seeking $15M in Series A funding to manufacture its drug to treat inflammatory diseases

Aqualung Therapeutics Corp CEO Dr "Skip" Garcia joined Proactive at the Biotech Showcase 2020 in San Francisco. The Arizona-based, privately-held early stage biotech company is involved in the treatment of inflammatory diseases, and is seeking $50M in Series A funding to manufacture its drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

NQ Minerals' David Lenigas says 44% boost to Hellyer production is 'biggest...

NQ Minerals PLC's (LON:NQMI) tells Proactive London's Andrew Scott that the plant upgrade at the Hellyer Gold Mine in Tasmania has resulted in a 44% increase in production. The enhancements, done six months ahead of expectation, have resulted in hourly production of 150 tonnes, which equates to...

5 hours, 34 minutes ago

2 min read